A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
OncoResponse, Inc.
Kineta Inc.
Charite University, Berlin, Germany
SpeciCare
Shenzhen BinDeBio Ltd.
Mie University
Shenzhen Second People's Hospital